VEGF-A drugs for Non-Small Cell Lung Cancer
11 tracked VEGF-A drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the VEGF-A page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
7 approved / phase 44 Phase 3
Head-to-head evidence: Alymsys (bevacizumab-maly) vs BAT1706 · Alymsys (bevacizumab-maly) vs Bevacizumab · Alymsys (bevacizumab-maly) vs HD204 · Alymsys (bevacizumab-maly) vs HLX04 · Alymsys (bevacizumab-maly) vs IBI305 · Alymsys (bevacizumab-maly) vs LY01008